IL-6, IL-8, IP-10, MCP-1 and G-CSF are significantly increased in cerebrospinal fluid but not in sera of patients with central neuropsychiatric lupus erythematosus

Lupus

Volumn 25, Issue 9, 2016, Pages 997-1003

  Yoshio, T ^a   Okamoto, H ^b   Kurasawa, K ^c   Dei, Y ^d   Hirohata, S ^e   Minota, S ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Minami Otsuka Clinic   (Japan)

^c DOKKYO MEDICAL UNIVERSITY   (Japan)

^d Dei Clinic   (Japan)

^e KITASATO UNIVERSITY   (Japan)

Author keywords

antiribosomal P protein antibodies; Central neuropsychiatric lupus erythematosus; cerebrospinal fluid; G CSF; IL 6; IL 8; IP 10; MCP 1

Indexed keywords

ALPHA INTERFERON; ANTIBODY; EOTAXIN; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCINE DEHYDROGENASE (DECARBOXYLATING); GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PREDNISOLONE; RANTES; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; CCL2 PROTEIN, HUMAN; CHEMOKINE; CXCL10 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; IL8 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SERODIAGNOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; BRAIN VASCULITIS; CEREBROSPINAL FLUID; IMMUNOLOGY; MIDDLE AGED; UPREGULATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHEMOKINE CCL2; CHEMOKINE CXCL10; CHEMOKINES; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MALE; MIDDLE AGED; UP-REGULATION; YOUNG ADULT;

EID: 84978267433     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203316629556     Document Type: Article

References (31)

1. Hanly JG, Liang MH,. Cognitive disorders in systemic lupus erythematosus: epidemiologic and clinical issues. Ann NY Acad Sci 1997; 823: 60-68.
2. Hanly JG. Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol 2014; 10: 338-47.
3. Gibson T, Myers AR,. Nervous system involvement in systemic lupus erythematosus. Ann Rheum Dis 1975; 35: 398-406.
4. Harris EN, Hughes GR,. Cerebral disease in systemic lupus erythematosus. Springer Semin Immunopathol 1985; 8: 251-266.
5. Trysberg E, Carlsten H, Tarkowski A,. Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. Lupus 2000; 9: 498-503.
6. Svenungsson E, Andersson M, Brundin L, et al. Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus. Ann Rheum Dis 2001; 60: 372-379.
7. Iikuni N, Okamoto H, Yoshio T, et al. Raised monocyte chemotactic protein-1 (MCP-1)/CCL2 in cerebrospinal fluid of patients with neuropsychiatric lupus. Ann Rheum Dis 2006; 65: 253-256.
8. Okamoto H, Iikuni N, Kamitsuji S, Yoshio T, Minota S, Kamatani N,. IP-10/MCP-1 ratio in CSF is an useful diagnostic marker of neuropsychiatric lupus patients. Rheumatology 2006; 45: 232-234.
9. Okamoto H, Katsumata Y, Nishimura K, Kamatani N,. Interferon-inducible protein 10/CXCL10 is increased in the cerebrospinal fluid of patients with central nervous system lupus. Arthritis Rheum 2004; 50: 3731-3732.
10. Fragoso-Loyo H, Richaud-Patin Y, Orozco-Narváez A, et al. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum 2007; 56: 1242-1250.
11. Gilad R, Lampl Y, Eshel Y, Barak V, Sarova-Pinhas I,. Cerebrospinal fluid soluble interleukin-2 receptor in cerebral lupus. Br J Rheumatol 1997; 36: 190-193.
12. Jönsen A, Bengtsson AA, Nived O, et al. The heterogeneity of neuropsychiatric systemic lupus erythematosus is reflected in lack of association with cerebrospinal fluid cytokine profiles. Lupus 2003; 12: 846-850.
13. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
14. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599-608.
15. Bombardier C, Gladman D, Urowitz M, Caron D, Chang C,. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-640.
16. Yoshio T, Masuyama J, Ikeda M, et al. Quantification of antiribosomal P0 protein antibodies by ELISA with recombinant P0 fusion protein and their association with central nervous system disease in systemic lupus erythematosus. J Rheumatol 1995; 22: 1681-1687.
17. Yoshio T, Hirata D, Onda K, Nara H, Minota S,. Antiribosomal P protein antibodies in cerebrospinal fluid are associated with neuropsychiatric systemic lupus erythematosus. J Rheumatol 2005; 32: 34-39.
18. Okamoto H, Kobayashi A, Yamanaka H,. Cytokines and chemokines in neuropsychiatric syndromes of systemic lupus erythematosus. J Biomed Biotechnol 2010; 2010: 268436-268436.
19. Hirohata S, Miyamoto T,. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum 1990; 33: 644-649.
20. Hirohata S, Hayakawa K,. Enhanced interleukin-6 messenger RNA expression by neuronal cells in a patient with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1999; 42: 2729-2730.
21. Hirohata S, Kanai Y, Mitsuo A, Tokano Y, Hashimoto H,. Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. Clin Rheumatol 2009; 28: 1319-1323.
22. Trysberg E, Nylen K, Rosengren LE, Tarkowski A,. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum 2003; 48: 2881-2887.
23. Matsushita T, Tateishi T, Isobe N, et al. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoSOne 2013; 8: e61835-e61835.
24. Lenhoff S, Rosberg B, Olofsson T,. Granulocyte interactions with GM-CSF and G-CSF secretion by endothelial cells and monocytes. Eur Cytokine Netw 1999; 10: 525-532.
25. Schneider A, Kruger C, Steigleder T, et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest 2005; 115: 2083-2098.
26. Pitzer C, Krüger C, Plaas C, et al. Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis. Brain 2008; 131: 3335-3347.
27. Yoshio T, Okamoto H, Hirohata S, Minota S,. Anti-NR2 glutamate receptor auto-IgG antibodies from patients with systemic lupus erythematosus activate endothelial cells. Arthritis Rheum 2013; 65: 457-463.
28. Cassatella MA, Gasperini S, Calzetti F, Bertagnin A, Luster AD, McDonald PP,. Regulated production of the interferon-gamma-inducible protein-10 (IP-10) chemokine by human neutrophils. Eur J Immunol 1997; 27: 111-115.
29. Deshmane SL, Kremlev S, Amini S, Sawaya BE,. Monocyte Chemoattractant Protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009; 29: 313-326.
30. Yoshio T, Masuyama J, Kano S,. Antiribosomal P0 protein antibodies react with the surface of human umbilical vein endothelial cells. J Rheumatol 1996; 23: 1311-1312.
31. Yoshio T, Okamoto H,. Pathogenesis of neuropsychiatric syndromes of systemic lupus erythematosus. Open J Rheumatol Autoimmun Dis 2015; 5: 46-56.